Drugs / THR100
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01305226 | Oct 2010 → Aug 2011 | acute myocardial infarction | Bharat Biotech International Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THR100 | “To demonstrate efficacy of THR100 as compared with streptokinase by assessment of 12-lead Electrocardiogram, specific cardiac Enzymes levels, pain relief and TIMI-90.” NCT01305226 ↗ |
| Modality | Protein / enzyme biologic | “This novel fibrinolytic agent is a 136 amino acid single chain protein secreted by some strains of Staphylococcus aureus and readily produced by recombinant DNA technology.” NCT01305226 ↗ |
| Route | Intravenous | “Dose levels (all administered intravenously).” NCT01305226 ↗ |